The pace of drug discovery has slowed down a bit since the early 2000s, and it’s unlikely to improve anytime soon.

The major milestones for all drugs are marked on a graph, with red for “proceedings” and blue for “final product” (see graphic above).

The number on the graph indicates how much work is required to reach the milestone, with the bigger the number, the faster progress is being made.

For the past decade, the progress rate for all major medicines has averaged about 0.9 per cent per year, with only one major breakthrough in the last decade.

As such, there’s no sign of a return to pre-2000 levels of development.

In the decade since the first milestone was reached, there have been eight major advances, five of which have been in the past 10 years.

“The pace of research and development in the United States is down significantly since the 1990s,” said Dr Scott Weyandt, CEO of Medtech Research, a company that tracks research spending in the US.

“We’ve seen a steady decline in research activity.”

That decline is largely due to the financial difficulties of the healthcare industry, which has been hammered by the coronavirus pandemic and is now spending less on research than it was a decade ago.

A decline in pharmaceutical development has had a ripple effect on the pharmaceutical market.

There have been a lot of drug approvals this year, which is a good sign for the future, but also puts a spotlight on how much progress has been made in the drug space over the past several years.

It’s also a reminder that the market for drugs is expected to grow even more over the next decade, with companies looking to take advantage of the rapid expansion in the medical technology market.

The latest update from the US Centers for Disease Control and Prevention shows the number of people living with chronic diseases increased by 10 per cent in 2016, which was a sharp jump from the previous year.

And a big jump in the number who are living with an autoimmune disease has been also a boon for the market.

However, there are still a lot more people who are sick than before, and they’re taking much longer to get to the stage where they’re no longer going to need the drugs.

There is also still a big gap between those who are going to be able to benefit from treatments and those who won’t.

This is reflected in the overall number of new infections in the U.S. in 2017.

There were 6.6 million new infections last year, a decrease of 6 per cent from the year before.

And although the number is down, the number in the states of Colorado, Florida, Texas and New York are still rising.

There are still about 2.7 million people living in the USA who have chronic diseases, according to the CDC.

The reason for the large drop in new infections was because of a new strain of the coronovirus, which killed an estimated 2.5 million people in the world last year.

While the number overall is still down, a lot has changed in the healthcare space since 2016.

Since the coronivirus pandemics, companies have started investing in developing new therapies and drugs that are able to fight the pandemic.

One of the first drugs that was approved for the treatment of the disease was a small molecule from the University of California, San Francisco.

Known as ZMapp, it’s a drug that’s used to treat a type of lung cancer called PD-L1, which can be triggered by the virus.

In humans, it can reduce the amount of virus in the body, and prevent it from causing any serious side effects.

It has shown to have significant efficacy in people who have been exposed to the virus, and is the first of its kind to be tested on humans.

The US has been the first country to have the drug licensed to be used in humans, and the first to start commercial trials in a number of other countries.

The results from the trials are expected to be available by the end of this year.

“ZMapp is showing some promise, but there are a lot challenges to overcome before it can be considered as a treatment for any of these patients,” said Professor David Rifkin, director of the US National Institute of Allergy and Infectious Diseases.

The drug also has some other advantages. “

However, there is evidence that antibodies that can block viral replication have shown some promise in treating some of the other conditions associated with this pandemic.”

The drug also has some other advantages.

It doesn’t need to be given continuously, meaning that it can help people who don’t have the capacity to produce enough antibodies to fight off the virus and help them live longer.

“This is one of the greatest surprises in pharmaceuticals over the